Mitesh Borad
Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
6
all conditions, ClinicalTrials.gov
NIH grants tied to them
5
NIH RePORTER
Trial papers
60
PubMed author-name match
Trials
Studies that name Mitesh Borad as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03377179 · A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaRedHill Biopharma Limited · completed · Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar · principal investigator
- Early Ph1NCT02646319 · Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR MutationsMayo Clinic · completed · Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma · principal investigator
- Ph2NCT02265341 · Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 FusionsMayo Clinic · completed · Malignant Hepatobiliary Neoplasm · principal investigator
- Ph1/Ph2NCT02128282 · Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of CholangiocarcinomaSenhwa Biosciences, Inc. · completed · Cholangiocarcinoma · principal investigator
- Ph2NCT01144455 · Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic AdenocarcinomaImmunoGenesis · completed · Pancreatic Adenocarcinoma · principal investigator
- Ph1/Ph2NCT00743379 · Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid TumorsThreshold Pharmaceuticals · completed · Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- New Therapuetics for Pancreatic CancerR01CA265050 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2024 to 2026 · $598,329 awarded in 2026Same name and institution; not confirmed by an ID
- HRD-IA signatures in pancreatic ductal adenocarcinomaUH3CA238926 · NCI · MAYO CLINIC ARIZONA · fiscal years 2024 · $325,709 awarded in 2024Same name and institution; not confirmed by an ID
- Gene and Virus Therapy ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2021 to 2023 · $43,250 awarded in 2023Grant number is on one of their registry trials
- Oncolytic Virotherapy in Hepatocellular CancerDP2CA195764 · NCI · MAYO CLINIC ARIZONA · fiscal years 2014 to 2016 · $219,502 awarded in 2016Same name and institution; not confirmed by an ID
- Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular CarcinomaR01FD004781 · FDA · MAYO CLINIC ARIZONA · fiscal years 2014 to 2016 · $199,637 awarded in 2016Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:51 UTC. The ranking covers the 200 most relevant of 60 PubMed records, and a shared surname and initials can bring in a namesake. All 60 on PubMed
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol · 20201,327 citationsRCR 56.9
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol · 2020931 citationsRCR 37.6
- Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.J Clin Oncol · 2011883 citationsRCR 22.9
- Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.N Engl J Med · 2009874 citationsRCR 19.6
- Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.Br J Cancer · 2020835 citationsRCR 42.2
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.Invest New Drugs · 2017737 citationsRCR 27.6
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.J Clin Oncol · 2018541 citationsRCR 17.7
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial.Nat Med · 2020493 citationsRCR 19.5
- Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.Clin Cancer Res · 2011442 citationsRCR 11.0
- 432 citationsRCR 22.7